NovaBay Pharmaceuticals (NYSE:NBY) announced today that it closed its previously announced acquisition of skincare treatment developer Dermadoctor.
Emeryville, California-based NovaBay develops the Avenova antimicrobial lid and lash spray, the CelleRx clinical reset and the NeutroPhase skin and wound cleanser for wound healing, all formulated with its patented, pure, stable, pharmaceutical-grade hypochlorous acid.
NovaBay was advised in the acquisition by Two Roads Advisors.
“Now that we have officially closed on the acquisition, it is time to start realizing synergies and growing our combined businesses. On our conference call later this week we will discuss the many benefits we see from the Dermadoctor acquisition in addition to detailing our third-quarter financial results,” NovaBay CEO Justin Hall said in a news release. “The timing of this earnings call allows us to recap recent accomplishments and share some detail on our strategic vision going forward.”